News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
477,909 Results
Type
Article (53173)
Company Profile (98)
Press Release (424638)
Section
Business (136951)
Career Advice (1613)
Deals (21662)
Drug Delivery (48)
Drug Development (60738)
Employer Resources (128)
FDA (10120)
Job Trends (10661)
News (230715)
Policy (19196)
Tag
Academia (2779)
Africa (664)
Alliances (38833)
Alzheimer's disease (1044)
Approvals (10090)
Arizona (82)
Artificial intelligence (51)
Asia (30163)
Australia (5736)
Bankruptcy (143)
Best Places to Work (8191)
Biotechnology (58)
C2C Services and Suppliers (42804)
California (1094)
Canada (587)
Cancer (263)
Career advice (1347)
Cell therapy (81)
China (93)
Clinical research (46442)
Collaboration (92)
Colorado (43)
Connecticut (42)
COVID-19 (2216)
Cystic fibrosis (51)
Data (138)
Diabetes (42)
Diagnostics (4347)
Drug pricing (41)
Earnings (46403)
Employer resources (112)
Europe (71683)
Events (59966)
Executive appointments (82)
FDA (10247)
Florida (166)
Funding (88)
Gene therapy (62)
Georgia (46)
GLP-1 (388)
Government (2864)
Healthcare (13547)
Hotbed/Location (300031)
Illinois (187)
Indiana (93)
Infectious disease (2230)
Inflammatory bowel disease (73)
Interviews (310)
IPO (9662)
Job creations (2508)
Job search strategy (1176)
Kansas (62)
Layoffs (246)
Legal (3608)
Liver cancer (38)
Lung cancer (64)
Management (40)
Manufacturing (51)
Maryland (245)
Massachusetts (775)
Medical device (8031)
Medtech (8033)
Mergers & acquisitions (11972)
Metabolic disorders (137)
Michigan (83)
Minnesota (132)
Neuroscience (1147)
New Jersey (399)
New York (415)
NextGen Class of 2024 (4567)
Non-profit (4147)
North Carolina (392)
Northern California (528)
Obesity (80)
Ohio (71)
Opinion (139)
Pennsylvania (315)
People (40654)
Phase I (13828)
Phase II (20223)
Phase III (15869)
Pipeline (93)
Policy (40)
Postmarket research (2202)
Preclinical (7049)
Press Release (68)
Rare diseases (80)
Real estate (4449)
Recruiting (49)
Regulatory (13344)
Research institute (2562)
Resumes & cover letters (226)
South America (821)
Southern California (456)
Startups (2731)
Texas (134)
United States (5161)
Vaccines (406)
Washington State (187)
Weight loss (64)
Date
Today (55)
Last 7 days (344)
Last 30 days (1595)
Last 365 days (26245)
2024 (17485)
2023 (28519)
2022 (38671)
2021 (41611)
2020 (39222)
2019 (33741)
2018 (25679)
2017 (23787)
2016 (23484)
2015 (27835)
2014 (21052)
2013 (18346)
2012 (18603)
2011 (19508)
2010 (18070)
477,909 Results for "emd group emd serono research institute billerica".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced new research from the company’s diverse oncology portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4, Chicago.
May 23, 2024
·
32 min read
Biotech Beach
EMD Serono and Takeda Join Rancho Biosciences as Charter Members of the Spatial Innovation Initiative
Rancho Biosciences is pleased to announce its partnership with EMD Serono, Takeda and a top 10 pharma company as charter members of the groundbreaking Spatial Innovation Initiative.
February 6, 2024
·
2 min read
Genetown
EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the presentation of two new post-hoc analyses of tertiary endpoints from the MAGNIFY-MS study, a Phase IV, prospective, open-label study evaluating the efficacy and safety of MAVENCLAD® tablets in highly active relapsing multiple sclerosis.
February 29, 2024
·
13 min read
Genetown
EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023
EMD Serono announced that 28 abstracts featuring the latest research on the company’s oncology portfolio addressing unmet needs across bladder, head and neck, lung, colorectal and other cancers, will be presented at the 2023 European Society of Medical Oncology Annual Meeting, October 20-24, Madrid, Spain.
October 16, 2023
·
28 min read
Business
EMD Serono Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced that it plans to move its U.S. Healthcare headquarters, currently located in Rockland, Mass., to Boston’s Seaport district.
November 14, 2023
·
3 min read
Genetown
EMD Serono Launches New Collaboration with United Nations’ Global Initiative on Ageing to Support Caregivers
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, announced a new collaboration with the United Nations’ Global Initiative on Ageing to provide a training course on critical skills for family caregivers.
October 5, 2023
·
4 min read
Genetown
EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the presentation of new analyses from the MAVENCLAD® tablets MAGNIFY-MS study, which demonstrated that patients with relapsing multiple sclerosis experienced sustained reduction in serum neurofilament light chain, indicating that MAVENCLAD reduced neuronal injury over two years.
October 10, 2023
·
12 min read
Job Trends
Merck KGaA, Darmstadt, Germany’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment
Merck KGaA, Darmstadt, Germany, a leading science and technology company that operates its Healthcare business as EMD Serono in the US and Canada, today shared updates on the company’s oncology pipeline and focused approach to the research and development of potential new medicines designed to improve the futures of people with cancer.
June 3, 2024
·
8 min read
Genetown
EMD Serono Highlights New Four-Year Efficacy and Safety Data for Investigational BTK Inhibitor, Evobrutinib, in RMS
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced updated long-term efficacy and safety data for investigational evobrutinib that continue to show a favorable safety and tolerability profile, consistent with what was seen earlier in the double-blind period (DBP) of the clinical trials.
February 23, 2023
·
14 min read
Business
Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development
Caris Discovery™, the therapeutic research arm of Caris Life Sciences®, the leading next-generation AI TechBio company and precision medicine pioneer, announced a multi-year strategic partnership with Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, to accelerate the discovery and development of first-in-class antibody-drug conjugates for cancer patients.
April 4, 2024
·
3 min read
1 of 47,791
Next